Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. 2012

Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

OBJECTIVE The distribution of folate receptor (FR)-β+ macrophages and their M1/M2 expression profiles were examined in osteoarthritis (OA) synovial tissues, and compared to those in rheumatoid arthritis (RA) synovial tissues and CD163+ macrophages in both OA and RA synovial tissues. METHODS The phenotypes and fluorescein isothiocyanate (FITC)-folate uptake of FR-β+ synovial macrophages were analysed by flow cytometry. The distribution of FR-β+ macrophages in OA and RA synovial tissues was examined by immunofluorescent microscopy. Tumour necrosis factor (TNF)-α, inducible nitric oxide synthase (iNOS), interleukin (IL)-10, and transforming growth factor (TGF)-β expression in FR-β+ macrophages was detected by double-immunostaining in both OA and RA synovial tissues. RESULTS FR-β+ macrophages were predominantly present in the synovial lining layer in OA patients. The proportion of CD163-FR-β+ cells in synovial mononuclear cells (MNCs) was increased in OA compared to RA synovial tissues. FR-β(high) macrophages from OA synovial tissues represented the majority of folic acid-binding cells. Although FR-β+ or CD163+ macrophages in the synovial tissues of OA and RA patients expressed a mixed pattern of M1 and M2 macrophage markers, there were more M2 markers expressing synovial macrophages in OA than in RA patients. CONCLUSIONS The distribution and M1/M2 expression profiles of FR-β+ synovial macrophages were different between OA and RA synovial tissues. Thus, the findings underscore that the M1/M2 paradigm using surface markers FR-β and CD163 is an oversimplification of macrophage subsets. Functional FR-β present on OA synovial macrophages provides a potential tool for the diagnosis and treatment of OA.

UI MeSH Term Description Entries
D007719 Knee Joint A synovial hinge connection formed between the bones of the FEMUR; TIBIA; and PATELLA. Superior Tibiofibular Joint,Joint, Knee,Joint, Superior Tibiofibular,Knee Joints,Superior Tibiofibular Joints,Tibiofibular Joint, Superior
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
August 2023, Clinical science (London, England : 1979),
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
January 2017, BioMed research international,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
April 2018, Cartilage,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
January 2020, Methods in molecular biology (Clifton, N.J.),
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
January 2014, Frontiers in immunology,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
December 2009, Cancer research,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
August 2022, International journal of molecular sciences,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
December 1982, Life sciences,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
December 2018, Experimental and therapeutic medicine,
Y Tsuneyoshi, and M Tanaka, and T Nagai, and N Sunahara, and T Matsuda, and T Sonoda, and K Ijiri, and S Komiya, and T Matsuyama
October 1988, European journal of pharmacology,
Copied contents to your clipboard!